ATE378594T1 - Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden synthetischen produktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung neuer kombinatorischer interventionen - Google Patents

Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden synthetischen produktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung neuer kombinatorischer interventionen

Info

Publication number
ATE378594T1
ATE378594T1 AT04774923T AT04774923T ATE378594T1 AT E378594 T1 ATE378594 T1 AT E378594T1 AT 04774923 T AT04774923 T AT 04774923T AT 04774923 T AT04774923 T AT 04774923T AT E378594 T1 ATE378594 T1 AT E378594T1
Authority
AT
Austria
Prior art keywords
disease
biological profile
determining
impact
group
Prior art date
Application number
AT04774923T
Other languages
English (en)
Inventor
Mei Wang
Renger Witkamp
Der Greef Jan Van
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE378594T1 publication Critical patent/ATE378594T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT04774923T 2003-09-05 2004-09-03 Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden synthetischen produktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung neuer kombinatorischer interventionen ATE378594T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03077804A EP1512970A1 (de) 2003-09-05 2003-09-05 Verfahren zur Bestimmung der Wirkung einer Zusammensetzung auf das Profil einer Krankheit

Publications (1)

Publication Number Publication Date
ATE378594T1 true ATE378594T1 (de) 2007-11-15

Family

ID=34130247

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04774923T ATE378594T1 (de) 2003-09-05 2004-09-03 Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden synthetischen produktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung neuer kombinatorischer interventionen
AT04774922T ATE378593T1 (de) 2003-09-05 2004-09-03 Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden naturproduktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung und qualitätskontrolle von medizin auf naturproduktbasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04774922T ATE378593T1 (de) 2003-09-05 2004-09-03 Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden naturproduktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung und qualitätskontrolle von medizin auf naturproduktbasis

Country Status (10)

Country Link
US (2) US20070020180A1 (de)
EP (3) EP1512970A1 (de)
JP (2) JP4675896B2 (de)
CN (2) CN1875273A (de)
AT (2) ATE378594T1 (de)
DE (2) DE602004010155T2 (de)
DK (2) DK1664770T3 (de)
EA (1) EA011959B1 (de)
ES (2) ES2297476T3 (de)
WO (2) WO2005024421A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
EP1512970A1 (de) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verfahren zur Bestimmung der Wirkung einer Zusammensetzung auf das Profil einer Krankheit
US7729789B2 (en) * 2004-05-04 2010-06-01 Fisher-Rosemount Systems, Inc. Process plant monitoring based on multivariate statistical analysis and on-line process simulation
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008120105A2 (en) * 2007-03-30 2008-10-09 9898 Limited Pharmaceutical platform technology for the development of natural products
DE102008011013B4 (de) * 2008-02-25 2014-11-13 Mevitec Gmbh Verfahren und Einrichtung zur komplexen Stoffwechselanalyse
KR101144237B1 (ko) * 2009-12-29 2012-05-11 한국기초과학지원연구원 고분해능 질량분석법과 약리활성검사를 이용한 천연물의 약리 활성물질 발굴 방법
AU2012223136B2 (en) 2011-03-02 2017-05-25 Berg Llc Interrogatory cell-based assays and uses thereof
WO2013151577A1 (en) * 2012-04-02 2013-10-10 Berg Pharma Llc Interrogatory cell-based assays and uses thereof
JP2014020831A (ja) * 2012-07-13 2014-02-03 Kyoto Univ 混合物試料の属性を識別する方法及び装置
JP2016530500A (ja) * 2013-07-01 2016-09-29 イクセラ，インコーポレイテッド システム生物学的アプローチによる療法
WO2016039348A1 (ja) * 2014-09-10 2016-03-17 一般財団法人ニッセンケン品質評価センター タンパク質繊維の鑑別方法
EP3191975A4 (de) 2014-09-11 2018-04-18 Berg LLC Bayes-kausalbeziehung-netzwerkmodelle zur gesundheitswesensdiagnose und -behandlung auf basis von patientendaten
CN109115904B (zh) * 2018-07-25 2021-02-02 山西广誉远国药有限公司 一种定坤丹uplc指纹图谱的构建方法及其应用
CA3146525A1 (en) 2019-08-05 2021-02-11 William Manning Systems and methods for sample preparation, data generation, and protein corona analysis
CN111180007A (zh) * 2019-12-03 2020-05-19 深圳市开物成务中医药科技有限公司 一种安全、有效、高质量中药开发平台系统及实现方法
CN111060640A (zh) * 2019-12-27 2020-04-24 深圳市开物成务中医药科技有限公司 测定与胰岛素耐受性相关的血脂谱的方法、应用及装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US5563043A (en) * 1994-10-24 1996-10-08 Spiral Biotech, Inc. Method for measuring the bactericidal and bacteriostatic effects of antimicrobial agents
US6379714B1 (en) * 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
WO1997020076A1 (en) * 1995-11-29 1997-06-05 Nexstar Pharmaceuticals, Inc. Methods for optimizing multicomponent formulations
JP3978529B2 (ja) * 1998-08-03 2007-09-19 大正製薬株式会社 冬虫夏草の判別法
US20030044846A1 (en) * 2001-04-03 2003-03-06 Gary Eldridge Screening of chemical compounds purified from biological sources
JP2003525622A (ja) * 2000-03-09 2003-09-02 エール ユニヴァーシティ フィトミクス：薬草組成物へのゲノムをベースとしたアプローチ
US20020095260A1 (en) * 2000-11-28 2002-07-18 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers
CA2457432A1 (en) * 2001-08-13 2003-02-27 Jan Van Der Greef Method and system for profiling biological systems
TW573125B (en) * 2001-08-29 2004-01-21 Combinatorx Inc A screening system for identifying drug-drug interactions and methods of use thereof
EP1512970A1 (de) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verfahren zur Bestimmung der Wirkung einer Zusammensetzung auf das Profil einer Krankheit
AU2006207954A1 (en) * 2005-01-28 2006-08-03 Childrens Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers

Also Published As

Publication number Publication date
EP1664770B1 (de) 2007-11-14
ES2297476T3 (es) 2008-05-01
WO2005024420A1 (en) 2005-03-17
DK1664767T3 (da) 2008-03-25
JP4675896B2 (ja) 2011-04-27
US20070020180A1 (en) 2007-01-25
DE602004010155T2 (de) 2008-09-25
DK1664770T3 (da) 2008-03-25
EA011959B1 (ru) 2009-06-30
EP1664767A1 (de) 2006-06-07
EA200600539A1 (ru) 2006-08-25
ATE378593T1 (de) 2007-11-15
CN1875273A (zh) 2006-12-06
WO2005024421A1 (en) 2005-03-17
DE602004010154T2 (de) 2008-09-25
EP1664770A1 (de) 2006-06-07
CN1875274A (zh) 2006-12-06
EP1512970A1 (de) 2005-03-09
JP2007510132A (ja) 2007-04-19
EP1664767B1 (de) 2007-11-14
JP2007508603A (ja) 2007-04-05
ES2297475T3 (es) 2008-05-01
DE602004010155D1 (de) 2007-12-27
DE602004010154D1 (de) 2007-12-27
US20070160990A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
ATE378594T1 (de) Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden synthetischen produktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung neuer kombinatorischer interventionen
ATE486844T1 (de) Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
Matesanz et al. Estimating belowground plant abundance with DNA metabarcoding
WO2010144150A3 (en) Real-time analytical methods and systems
BRPI0417780A (pt) composto, processo para preparar o mesmo, agente, processos para preparar o mesmo, e para combater vegetação indesejada, e, uso de um composto
BRPI0407397A (pt) Evento de algodão mon 88913 e composições e métodos para sua detecção
DE602006007862D1 (de) Verfahren zur herstellung eines rtm-verbundteils und mit diesem verfahren hergestellte verbundpleuelstange
AR061180A1 (es) Metodo para identificar loci de caracteristicas cuantitativas de resistencia a enfermedades en soja y composiciones de los mismos
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
BR112013009713A2 (pt) método para identificação de alta produtividade antagonistas microbianos contra patógenos
ATE534909T1 (de) Verfahren zur proteomischen profilierung mithilfe nichtnatürlicher aminosäuren
ATE456048T1 (de) Verfahren zur beurteilung von immunreaktionen
DE602007000275D1 (de) Verfahren der optischen Fluoreszenzbildgebung biologischer Gewebe, insbesondere zur Bestimmung von Interessengebieten für die Gewebeanalyse durch Tomographie
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
Rais et al. Impact of species mixture on the stiffness of European beech (Fagus sylvatica L.) sawn timber
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
ATE552506T1 (de) Verfahren zur herstellung einer standard- serumsmischung zur bestimmung der potenz eines allergens und anwendung der serumsmischung
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
DE50312587D1 (de) Verfahren zur herstellung von acrysäure und polymerisierbare verbindungen
PL2497486T3 (pl) Sposoby leczenia chorób powodowanych przez grzyby i pierwotniaki, związanych ze zmianami jakościowymi i/lub ilościowymi składu pozakomórkowego DNA krwi
ATE426581T1 (de) Verfahren zur auftrennung stereoisomerer verbindungen
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
DE60322240D1 (de) Katzenpankreas-lipase-zusammensetzung und verfahren zur herstellung und verwendung einer solchen zusammensetzung
Grossman et al. Non-symbiotic soil microbes are more strongly influenced by altered tree biodiversity than arbuscular mycorrhizal fungi during initial forest establishment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1664770

Country of ref document: EP